A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta-selective agonist in development for the treatment of NASH with liver fibrosis. METHODS: We are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The two primary end points at week 52 were NASH resolution (including a reduction in the nonalcoholic fatty liver disease [NAFLD] activity score by ≥2 points; scores range from 0 to 8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least one stage with no worsening of the NAFLD activity score. RESULTS: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (P<0.001 for both comparisons with placebo). Fibrosis improvement by at least one stage with no worsening of the NAFLD activity score was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (P<0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (P<0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group. CONCLUSIONS: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to NASH resolution and improvement in liver fibrosis by at least one stage. (Funded by Madrigal Pharmaceuticals; MAESTRO-NASH ClinicalTrials.gov number, NCT03900429.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Therefore, incretinbased medications for the treatment of MASLD could be made available, supplementing resmetirom as the only approved medication in the USA and Europe.87”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [87]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Resmetirom is the first compound approved for the treatment of MASH in conjunction with diet and exercise, showing the importance of combining lifestyle changes to pharmacological treatment.91”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was not until March 2024 that the U.S. Food and Drug Administration (FDA) approved the first drug, Rezdiffra, for non-alcoholic steatohepatitis (NASH) with liver fibrosis.”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Resmetirom, a THRβ agonist, showed antisteatogenic potential in a 36-week phase 2 RCT in people with biopsy-confirmed MASH and fibrosis, accompanied by a rise in circulating adiponectin and improved plasma lipid profile [210,211].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [211]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“About 14% of participants in the MAESTRO-NASH trial were on GLP1RA treatment, with stable dosage in the 6 months and stable body weight in the 3 months preceding screening liver biopsy.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [350]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationMechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citation
Research works printed but not linked: 2
- 24. Conduct of clinical trials of medical products during the COVID-19 public health emergency: guidance for industry, investigators, and institutional review boards. Silver Spring, MD: Food and Drug Administration, August 30, 2021 (https:// www . fda . gov/ media/ 136238/ download/ ). Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the
- 3. ogy/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
Cited by
Items 101–200 of 1,003
Jee, Y.-M., Lee, J., & Ryu, T. (2025) · Biomedicines · doi:10.3390/biomedicines13051260 · Cited by 71
“Resmetirom, a selective THR-β agonist, has demonstrated significant reductions in hepatic fat content, serum low-density lipoprotein cholesterol, and markers of fibrosis and inflammation in phase II and III trials [126,129].”
MASH clinical trials and drugs pipeline: An impending tsunami
Noureddin, M. (2025) · Hepatology · doi:10.1097/hep.0000000000000860 · Cited by 48
Self-citationFerdous, S.-E., & Ferrell, J. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168731 · Cited by 60
“The very recently USFDA approved (March 2024) drug Resmetirom is the only treatment option available for MASLD and MASH, though only 25% of patients saw improvement of fibrosis by one score with no worsening of fibrosis [11].”
BackgroundInfluentialDing, J., Liu, H., Zhang, X., Zhao, N., Peng, Y., Shi, J., Chen, J., Chi, X., Li, L., Zhang, M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adh9940 · Cited by 63
Israelsen, M. E., Thorhauge, K. H., Andersen, P., Johansen, S., Schnefeld, H. L., Bech, K., Hansen, J. K., Torp, N., Jensen, E. L., Hansen, E. D., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.007 · Cited by 62
A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite–CerS6–ceramide axis
Zhou, S., Li, M., Wang, P., Guo, C., Zhang, J., Luo, X., Fan, Y., Chen, E., Qi, X., Chen, J., et al. (2025) · Science · doi:10.1126/science.adp5540 · Cited by 60
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH
Alkhouri, N., Beyer, C., Shumbayawonda, E., Andersson, A., Yale, K., Rolph, T., Chung, R. T., Vuppalanchi, R., Cusi, K. J., Loomba, R. S., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.031 · Cited by 60
Self-citationNon-invasive testing in metabolic dysfunction-associated steatotic liver disease
Dawod, S. M., & Brown, K. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1499013 · Cited by 61
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Self-citationGuirguis, E. H., Dougherty, J., Thornby, K., Grace, Y., & Mack, K. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241259528 · Cited by 56
“6,7 This aligns with current guideline recommendations for the addition of lipid-lowering therapies, antihypertensives, and antidiabetic agents targeting cardiovascular health for both primary and secondary prevention in qualifying patients.”
Yang, C., Wu, J., Yang, L., Hu, Q., Li, L., Yang, Y., Jing Hua, H. U., Pan, D., & Zhao, Q. (2024) · Scientific Reports · doi:10.1038/s41598-024-72909-8 · Cited by 58
Sakuma, I., Gaspar, R. C., Nasiri, A. R., Dufour, S., Kahn, M., Zheng, J., LaMoia, T. E., Guerra, M. T., Taki, Y., Kawashima, Y., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502978122 · Cited by 46
Samy, A. M., Kandeil, M. A., Sabry, D., Abdel-Ghany, A. A., & Mahmoud, M. O. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30387 · Cited by 60
Mantovani, A., Csermely, A., Bilson, J., Borella, N., Enrico, S., Pecoraro, B., Shtembari, E., Morandin, R., Pοlyzos, S. A., Valenti, L. V. C., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332491 · Cited by 57
“10 Therefore, FDA conditionally approved it on 14 March 2024 resmetirom as the first drug for the treatment of adults with non-cirrhotic MASH and significant liver fibrosis 51 The present meta-analysis has important limitations inherent to the design of the eligible studies.”
BackgroundThe Role of Exercise in Steatotic Liver Diseases: An Updated Perspective
Razzak, I. A., Fares, A., Stine, J. G., & Trivedi, H. D. (2024) · Liver International · doi:10.1111/liv.16220 · Cited by 61
“The significance of thyroid-liver relationship on MASLD is highlighted by recent phase 3 clinical trial results, which demonstrate the efficacy of Resmetirom, a selective THR-β agonist, in resolving non-alcoholic steatohepatitis (NASH) and improving liver fibrosis [37].”
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 70
Adverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease
Ochoa‐Allemant, P., Hubbard, R. A., Kaplan, D. E., & Serper, M. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1809 · Cited by 63
Kim, S., Oh, J. S., Shin, J. I., Aalruz, H., Abbas, N., Babatope, A. E., Aboagye, R. G., Abohashem, S., Abu‐Zaid, A., Addo, I. Y., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00011-7 · Cited by 86
MASLD development: From molecular pathogenesis toward therapeutic strategies
Yang, Z., Zhao, J., Xie, K., Tang, C., Gan, C., & Gao, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003629 · Cited by 59
“[130] The United States Food and Drug Administration (FDA)’s approval of resmetirom on March 14, 2024, marked a significant milestone, as it became the first pharmacological agent to be authorized to manage MASH.”
(2025) · doi:10.1101/2025.02.25.640203 · Cited by 45
Rezdiffra™ (resmetirom): a THR-β agonist for non-alcoholic steatohepatitis
Brisnovali, N. F., Haney, C., & Goedeke, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.08.009 · Cited by 45
Pharmaco‐Economic Assessment of Screening Strategies for High‐Risk MASLD in Primary Care
Younossi, Z. M., Paik, J. M., Henry, L. L., Stepanova, M., & Nader, F. (2024) · Liver International · doi:10.1111/liv.16119 · Cited by 58
Self-citationPhosphatidylethanol in steatotic liver disease
Torp, N., Israelsen, M. E., Thiele, M. S., Rinella, M. E., & Krag, A. A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.07.019 · Cited by 55
Self-citationNoureddin, M., Harrison, S. A., Loomba, R. S., Alkhouri, N., Chalasani, N., Sheikh, M. Y., Tomah, S., Gutierrez, J. A., Urbina, S., Suschak, J. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02114-2 · Cited by 66
Self-citationLiver biopsy evaluation in MASH drug development: Think thrice, act wise
Harrison, S. A., & Dubourg, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.008 · Cited by 53
Self-citationIntegrating liver endpoints in clinical trials of cardiovascular and kidney disease
Zannad, F. M., Sanyal, A. J., Butler, J., Miller, V., & Harrison, S. A. (2024) · Nature Medicine · doi:10.1038/s41591-024-03223-z · Cited by 52
“Appropriate liver data, including NITs and other outcomes, should be prospectively collected—in consulta-tion with regulatory agencies regarding what evidence is needed for approvals.”
Self-citationArmandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156080 · Cited by 53
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 57
Younossi, Z. M., Stepanova, M., Racila, A., Henry, L. L., Labriola, D., Taub, R. A., & Nader, F. (2024) · Hepatology · doi:10.1097/hep.0000000000001084 · Cited by 47
Self-citationIncretin-based investigational therapies for the treatment of MASLD/MASH
Brouwers, B., Rao, G., Tang, Y., Rodríguez, Á., Glass, L. C., & Hartman, M. L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111675 · Cited by 40
First US drug approved for a liver disease surging around the world
Ledford, H. K. (2024) · Nature · doi:10.1038/d41586-024-00747-9 · Cited by 42
Jiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 50
“Recently, the published phase 3 trials showed that resmetirom significantly improved liver fibrosis and inflammation, and reduced LFC as well as serum LDL-c, ApoB, and TG concentrations [89, 90].”
BackgroundPetersen, K. F., Dufour, S., Mehal, W. Z., & Shulman, G. I. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.07.023 · Cited by 47
Hepatic immune regulation and sex disparities
Burra, P., Zanetto, A., Schnabl, B., Reiberger, T., Montaño‐Loza, A. J., Asselta, R., Karlsen, T. H., & Tacke, F. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00974-5 · Cited by 45
“However, for the currently approved MASH drug resmetirom (a thyroid hormone receptor β-selective agonist) 212 , no sex-specific analyses of treatment responses were reported, whereas sex hormone binding globulin seemed to be a predictor of histological response.”
MetALD: Clinical aspects, pathophysiology and treatment
Gratacós‐Ginès, J., Ariño, S., Sancho‐Bru, P., Bataller, R. A., & Pose, E. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101250 · Cited by 62
Lam, S. M., Wang, Z., Song, J., Shi, Y., Liu, W., Wan, L., Duan, K., Chua, G. H., Zhou, Y., Wang, G., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.009 · Cited by 51
Zisis, M., Chondrogianni, M. E., Ανδρουτσάκος, Θ., Rantos, I., Oikonomou, E. K., Chatzigeorgiou, A., & Kassi, E. N. (2025) · Biomolecules · doi:10.3390/biom15030324 · Cited by 48
“However, pharmacologic interventions with drugs targeting known modifiable cardiometabolic risk factors, such as hypertension, dyslipidemia, and T2DM, remain a reasonable and common strategy to prevent CVD development and progression of MASLD.”
Loomba, R. S., Morgan, E., Yousefi, K., Li, D., Geary, R. S., Bhanot, S., & Alkhouri, N. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00979-1 · Cited by 46
Self-citationCelsa, C., Pennisi, G., Tulone, A., Ciancimino, G., Vaccaro, M., Pecorella, F., Maria, G. D., Enea, M., Midiri, F., Mantovani, A., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00188-8 · Cited by 61
Self-citationSuresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Mehta, P. D., Damodaran, U. K., Brar, A., Sohal, A., Hatwal, J., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2025.0212 · Cited by 55
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Milani, I., Chinucci, M., Leonetti, F., & Capoccia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13040855 · Cited by 38
“In the phase 3 trials, MAESTRO-NAFLD-1 [294] and MAESTRO-MASH [295], resmetirom effectively reduced liver steatosis in non-cirrhotic MASH adults with significant liver fibrosis [296].”
Cuthbertson, D. J., Keating, S. E., Pugh, C. J. A., Owen, P. J., Kemp, G. J., Umpleby, M., Geyer, N. G., Chinchilli, V. M., & Stine, J. G. (2024) · Liver International · doi:10.1111/liv.15947 · Cited by 38
Arvanitakis, K., Chatzikalil, E., Kalopitas, G., Patoulias, D., Popovic, D. S., Metallidis, S., Kotsa, K., Germanidis, G. S., & Koufakis, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144243 · Cited by 45
“Recent conditional approval of resmetirom by the FDA, a thyroid hormone receptor-β -selective per os medication, is considered a major breakthrough in MASLD treatment, tailored for non-cirrhotic patients with MASH and moderate-to-advanced fibrosis [10,11].”
BackgroundAbdelnabi, M. N., Hassan, G. S., & Shoukry, N. H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1437046 · Cited by 46
Dixon, E. D., Claudel, T., Nardo, A. D., Riva, A., Fuchs, C. D., Mlitz, V., Busslinger, G. A., Scharnagl, H., Stojaković, T., Séneca, J., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.037 · Cited by 41
The steatotic liver disease burden paradox: unravelling the key role of alcohol
Torp, N., Israelsen, M. E., & Krag, A. A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01022-y · Cited by 47
“Inflammation is considered the driving force of profibrotic signalling in SLD. Drugs that can alleviate hepatic inflammation, such as the thyroid hormone receptor β-selective agonist resmetirom, might also prove effective in MetALD and ALD populations 115 .”
Thyroid Hormones and Metabolism Regulation: Which Role on Brown Adipose Tissue and Browning Process?
Sabatino, L., & Vassalle, C. (2025) · Biomolecules · doi:10.3390/biom15030361 · Cited by 59
“…reported the results from a phase 3 multinational, double-blind, randomized, placebo-controlled trial on the employment of Resmetirom (MGL-3196), a selective liver TR β agonist, developed for treatment of NASH, assessing the efficacy and safety in adults with confirmed diagnosis of NASH [68].”
Luo, X., Wang, K., & Jiang, C. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.04.020 · Cited by 45
Tantu, M. T., Farhana, F. Z., Haque, F., Koo, K. M., Qiao, L., Ross, A. G., & Shiddiky, M. J. A. (2025) · npj gut and liver. · doi:10.1038/s44355-025-00030-2 · Cited by 57
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
Li, W., Alazawi, W., & Loomba, R. S. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00260-2 · Cited by 57
Self-citationMetALD: Does it require a different therapeutic option?
Marek, G. W., & Malhi, H. (2024) · Hepatology · doi:10.1097/hep.0000000000000935 · Cited by 43
“[44] There are over 500 active or completed drug trials for MASLD and around 90 trials for ALD.”
Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
Fiorucci, S., Urbani, G., Distrutti, E., & Biagioli, M. (2025) · Pharmaceuticals · doi:10.3390/ph18091424 · Cited by 47
“Resmetirom has been the first drug approved for treatment of MASH in 2024 based on favorable results from the MAESTRO-NASH trial [131,132].”
Vuppalanchi, R., Loomba, R. S., Sanyal, A. J., Nikooie, A., Tang, Y., Robins, D. A., Brouwers, B., & Hartman, M. L. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18042 · Cited by 38
Self-citationCurrent Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
Devasia, A. G., Ramasamy, A., & Leo, C. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041778 · Cited by 48
“MASH resolution occurred in 25.9% (80 mg) and 29.9% (100 mg) of participants, compared to 9.7% in the placebo group [141].”
InfluentialMetabolic dysfunction and alcohol-associated liver disease (MetALD)
Gao, B., Arab, J. P., Liangpunsakul, S., Ding, W., Szabó, G., Mehal, W. Z., Wang, H., He, Y., Stärkel, P., Llorente, C., et al. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100319 · Cited by 54
“35 In a post hoc analysis, a fraction (10%–15”
Self-citationA Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis
Harrison, S. A., & Taub, R. A. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2402905 · Cited by 39
Self-citationDutta, D., Kamrul-Hasan, A. B. M., Mondal, E., Nagendra, L., Joshi, A., & Bhattacharya, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.04.016 · Cited by 43
A roadmap for clinical trials in MASH-related compensated cirrhosis
Pericàs, J. M., Anstee, Q. M., Augustín, S., Bataller, R. A., Berzigotti, A., Ciudin, A., Francque, S., Abraldeṣ, J. G., Hernández–Gea, V., Pons, M., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00955-8 · Cited by 41
“The publication of a positive trial in early February 2024 19 led to the first FDA approval of a drug to treat MASH 20 , the hepatic thyroid hormone receptor-β agonist resmetirom, which is now under consideration by EMA.”
Self-citationHudson, D., Afzaal, T., Bualbanat, H., AlRamdan, R., Howarth, N., Parthasarathy, P., Al-Darwish, A., Stephenson, E., Almahanna, Y., Hussain, M., et al. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241276334 · Cited by 50
“108,141 In addition, Tirzepatide, recently approved for type 2 diabetes mellitus as a dual agonist of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has shown benefits in improving MASH-related fibrosis according to recent findings published from the phase II…”
Stefanakis, K., Mingrone, G., George, J., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156082 · Cited by 39
Jiménez-González, C., Alonso‐Peña, M., Vélez, P. A., Crespo, J., & Iruzubieta, P. (2025) · Nutrients · doi:10.3390/nu17091580 · Cited by 46
“In 2024, Resmetirom received accelerated FDA approval for patients with MASLD and significant fibrosis, following promising—though modest—histological improvements observed in the interim analysis of a phase 3 clinical trial [5].”
InfluentialKey takeaways from the updated multidisciplinary European MASLD guidelines
Horn, P., & Tacke, F. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100196 · Cited by 43
“42 Based on the positive results of the phase III MAESTRO-NASH study, 43 the Food and Drug Administration (FDA) has granted accelerated approval for the thyroid hormone receptor β -agonist resmetirom for the treatment of non-cirrhotic MASH with significant fibrosis ( ≥ F2) in the USA.”
Wong, V. W., Amin, N. B., Takahashi, H., Darekar, A., Tacke, F., Kiszko, J., Rodriguez, H., Nakajima, A., Alkhouri, N., Charlton, M., et al. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00128-1 · Cited by 39
Self-citationRatti, C., Malaguti, M., D’Aniello, E., Bellasi, A., & Sanna, G. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120495 · Cited by 46
Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD
Long, X., Wang, H., Lu, Y., Gao, X., Xiao, Y., Zhang, M., Guo, J., Yang, H. J., Zhang, R., Li, Q., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.10.017 · Cited by 40
Bile acids regulate lipid metabolism through selective actions on fatty acid absorption
Chan, A. P., Jarrett, K. E., Lai, R. W., Brearley-Sholto, M. C., Cheng, A., Taveras, M. O., Iwata, A. M., Steel, M. E., Lau, A., Whang, E. C., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.11.010 · Cited by 42
Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom
Kuchay, M. S., Isaacs, S. D., & Misra, A. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103034 · Cited by 45
Kwon, Y., Gottmann, P., Wang, S., Tissink, J. J., Motzler, K., Sekar, R., Albrecht, W., Cadenas, C., Hengstler, J. G., Schürmann, A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.040 · Cited by 41
Resmetirom's approval: Highlighting the need for comprehensive approaches in NASH therapeutics
Alshehade, S. A. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102377 · Cited by 36
Moolla, A., Poolman, T., Othonos, N., Dong, J., Smith, K., Cornfield, T., White, S., Ray, D. W., Mouchti, S., Mózes, F. E., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101363 · Cited by 33
Lindfors, A., Strandberg, R., & Hagström, H. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00313-3 · Cited by 38
Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances
Zhao, L., Tang, H., & Cheng, Z. (2024) · Pharmaceuticals · doi:10.3390/ph17121724 · Cited by 40
MetALD : New Perspectives on an Old Overlooked Disease
Ayares, G., Díaz, L. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Bataller, R. A., Loomba, R. S., Arab, J. P., & Arrese, M. A. (2025) · Liver International · doi:10.1111/liv.70017 · Cited by 40
Self-citationPοlyzos, S. A., & Targher, G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16117 · Cited by 33
“66 This relatively low response rate is commonly observed in almost all MASLD clinical trials and might, at least partly, be attributed to the multifactorial pathogenesis of the disease 83 ; in other words, since different pathogenic factors have contributed to each patient with MASLD/MASH, one…”
InfluentialMetabolic Dysfunction and Alcohol-Associated Liver Disease: A Narrative Review
Dunn, N. R., Alkhouri, N., Ismail, A. S., & Singal, A. K. (2025) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000828 · Cited by 34
Self-citationResmetirom: The First Disease‐Specific Treatment for MASH
Mousa, A. M., Mahmoud, M., & AlShuraiaan, G. M. (2025) · International Journal of Endocrinology · doi:10.1155/ije/6430023 · Cited by 46
“Te pivotal MAESTRO-NASH trial [37], a Phase 3, randomized, double-blind, placebo-controlled study, assessed the efcacy of Resmetirom in patients with biopsy-confrmed NASH and fbrosis stages F2 to F3.”
The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC
Wu, Q., Yang, Y., Lin, S., Geller, D. A., & Yan, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1569915 · Cited by 32
Zhang, Z., Yang, H., Han, F., & Guo, P. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060464 · Cited by 43
“This breakthrough validates decades of research on NASH pathogenesis and establishes THR-β as a viable drug target [125].”
Tsochatzis, E. A., Valenti, L. V. C., Thiele, M. S., Péloquin, S., Lazure, P., Masson, M. H., Allen, A. M., Lazarus, J. V., Noureddin, M., Rinella, M. E., et al. (2024) · Liver International · doi:10.1111/liv.15941 · Cited by 34
“43 Our study found that clinicians perceived having limited capacity to enact behavioural change amongst patients.”
Self-citationRecompensation in MASLD-related cirrhosis via metabolic bariatric surgery
Feng, G., Han, Y., Yang, W., Shikora, S. A., Mahawar, K. K., Cheung, T. T., Targher, G., Byrne, C. D., Hernández–Gea, V., Tilg, H., et al. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.05.009 · Cited by 36
Oliveira, L. S. D., & Ritter, M. J. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000596 · Cited by 41
“[21] ( Clin-icalTrials.gov Identifier: NCT03900429).”
InfluentialClinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Díaz, L. A., Thiele, M. S., Louvet, A., Lee, B. P., Ajmera, V. H., Tavaglione, F., Hsu, C. L., Huang, D. Q., Pose, E., Bataller, R. A., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01120-5 · Cited by 38
“%) with respect to MASH resolution and improvement in liver fibrosis by at least one stage (NCT03900429) 169 .”
Self-citationNoureddin, M., Rinella, M. E., Taub, R. A., Labriola, D., Camacho, R. C., Alkhouri, N., Loomba, R. S., & Bansal, M. B. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70382 · Cited by 44
Self-citationPharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
Self-citationGraupera, I., Thiele, M. S., Castéra, L., Pera, G., Piano, S. S., Sòria, A., Fabrellas, N., Torán‐Monserrat, P., Chacón, C., Bech, K., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00354-5 · Cited by 35
Self-citationShi, H., Wang, X., Sloas, C., Gerlach, B., Yurdagul, A., Moore, M. P., Jung, E. J., Mirshahi, F., Ronzoni, L., Sanyal, A. J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv2106 · Cited by 30
Self-citationThe Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum
Vidal‐Cevallos, P., Sorroza-Martínez, A. P., Chávez-Tapia, N. C., Uribe, M., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084397 · Cited by 37
“Improvement of fibrosis in at least one stage without worsening of NAFLD activity score and reduction in cholesterol and low-density lipoprotein levels [128].”
BackgroundSajiir, H., Keshvari, S., Wong, K. Y., Borg, D. J., Steyn, F. J., Fercher, C., Taylor, K., Taylor, B., Barnard, R. T., Mueller, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48317-x · Cited by 35
Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis
Chen, J., Jian, L., Guo, Y., Tang, C., Huang, Z., & Gao, J. (2024) · Antioxidants · doi:10.3390/antiox13060729 · Cited by 39
“Despite considerable investigations into the underlying mechanisms, only resmetirom is now approved by the U.S. Food and Drug Administration (FDA) for the clinical treatment of MASH [7].”
BackgroundUnagolla, J. M., Das, S., Flanagan, R., Oehler, M., & Menon, J. U. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124381 · Cited by 33
Puengel, T., & Tacke, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2374463 · Cited by 34
“Based on data from a phase 3 clinical trial program, the U.S. Food and Drug Administration (FDA) has recently approved the thyroid hormone receptor β (THRβ)-selective thyromimetic resmetirom as the first and so far only medication for the indication of non-cirrhotic MASH [10,11].”
InfluentialPotential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 33
Koh, B., Xiao, J., Ng, C. H., Law, M., Gunalan, S. Z., Danpanichkul, P., Ramadoss, V., Sim, B., Tan, E. Y., Teo, C. B., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001028 · Cited by 33
Self-citationA new treatment and updated clinical practice guidelines for MASLD
Powell, E. E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01014-y · Cited by 32
“Harrison and colleagues determined the efficacy and safety of resmetirom during an ongoing 54-month, randomized, double-blind, placebo-controlled trial involving 966 patients with biopsy-confirmed MASH and largely moderate or severe fibrosis 7 .”
InfluentialSong, Y., Ni, W., Zheng, M., Sheng, H., Wang, J., Xie, S., Yang, Y., Chi, X., Chen, J., He, F., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.101939 · Cited by 46
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective
Zeng, X., Huang, D., Zhu, Z., Cai, Q., Yang, Y., Lu, H., & Chen, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574385 · Cited by 37
Ketogenesis supports hepatic polyunsaturated fatty acid homeostasis via fatty acid elongation
Queathem, E. D., Moazzami, Z., Stagg, D. B., Nelson, A. B., Fulghum, K., Hayir, A., Seay, A., Gillingham, J. R., d’Avignon, D. A., Han, X., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads0535 · Cited by 30
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Minetti, E. T., Hamburg, N. M., & Matsui, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1469492 · Cited by 38
Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)
Strandberg, T. E., Kovanen, P. T., Lloyd‐Jones, D. M., Raal, F. J., Santos, R. D., & Watts, G. F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02089-0 · Cited by 30
Metadata
- Authors
- Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., Anstee, Q. M., Abdelmalek, M. F., Younossi, Z., Baum, S. J., Francque, S., Charlton, M. R., Newsome, P. N., Lanthier, N., Schiefke, I., Mangia, A., Pericàs, J. M., Patil, R., Sanyal, A. J., Noureddin, M., Bansal, M. B., Alkhouri, N., Castera, L., Rudraraju, M., & Ratziu, V.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and Houston Methodist Hospital, Houston Research Institute, Houston (M.N.) — all in Texas; Liverpat and University of Paris (P.B.), INSERM, Unité Mixte de Recherche Scientifique (UMRS) 1139, Centre de Recherche sur l’Inflammation (L.C.), and Sorbonne Université, ICAN Institute for Cardiometabolism and Nutrition, Assistance Publique–Hôpitaux de Paris (APHP), INSERM, UMRS 1138, Centre de Recherche des Cordeliers (V.R.), Paris, and Université Paris-Cité, Department of Hepatology, Beaujon Hospital, APHP, Clichy (L.C.) — ...
- Universitat Autònoma de Barcelona (ES)
- Houston Methodist (US)
- ORCID
- Harrison, Stephen A.
- Guy, Cynthia D.
- Schattenberg, Jörn M.
- Loomba, Rohit
- Taub, Rebecca
- Neff, Guy W.
- Rinella, Mary E.
- Anstee, Quentin M.
- Abdelmalek, Manal F.
- Younossi, Zobair
- Baum, Seth J.
- Francque, Sven
- Charlton, Michael R.
- Newsome, Philip N.
- Lanthier, Nicolas
- Mangia, Alessandra
- Pericàs, Juan M.
- Patil, Rashmee
- Sanyal, Arun J.
- Noureddin, Mazen
- Bansal, Meena B.
- Alkhouri, Naim
- Rudraraju, Madhavi
- Ratziu, Vlad
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-02-08
- Volume
- 390
- Issue
- 6
- Pages
- 497-509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4391592880
- Cited by
- 2,084
- References
- 26
- Citations by year
- 2026: 797 · 2025: 807 · 2024: 478
- FWCI
- 635.31
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Open Access CRIS of the University of Bern
- Funders
- Madrigal Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- resmetirom, nonalcoholic steatohepatitis, liver fibrosis, thyroid hormone receptor beta agonist, NASH resolution, fibrosis regression, NAFLD activity score, LDL cholesterol, triglycerides, cirrhosis prevention, drug safety and tolerability
- MeSH terms
- Adult, Biopsy, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Liver, Liver Cirrhosis, Pyridazines, Uracil, Treatment Outcome, Thyroid Hormone Receptors beta, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.